公开(公告)号：US12084498B2

公开(公告)日：2024-09-10

申请号：US17388052

申请日：2021-07-29

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Hélène Sicard ,  Renaud Buffet

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/30 ,  G01N33/574

CPC classification number: C07K16/2803 ,  C07K16/3023 ,  C07K16/3061 ,  G01N33/57426 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/732 ,  G01N2333/705 ,  G01N2333/70503

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

公开(公告)号：US10344087B2

公开(公告)日：2019-07-09

申请号：US14767600

申请日：2014-02-13

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Hélène Sicard ,  Renaud Buffet ,  Mathieu Blery

IPC: A61K39/00 ,  C07K16/28 ,  C07K16/30 ,  G01N33/574

Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

公开(公告)号：US20150140000A1

公开(公告)日：2015-05-21

申请号：US14403171

申请日：2013-05-30

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Laurent Gauthier ,  Yannis Morel ,  Carine Paturel ,  Ivan Perrot

IPC: C07K16/28 ,  A61K47/48

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.

Abstract translation: 本文公开了抗TLR3抗体以及制备和使用它们的方法。 抗体特别适用于使用抗TLR3抗体治疗自身免疫性或炎性疾病。

公开(公告)号：US11999784B2

公开(公告)日：2024-06-04

申请号：US16451051

申请日：2019-06-25

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Hélène Sicard ,  Renaud Buffet ,  Mathieu Blery

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/574

CPC classification number: C07K16/28 ,  C07K16/2803 ,  C07K16/3061 ,  G01N33/57407 ,  C07K2317/73 ,  C07K2317/732 ,  G01N2333/70503

Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

公开(公告)号：US09944712B2

公开(公告)日：2018-04-17

申请号：US14403171

申请日：2013-05-30

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Laurent Gauthier ,  Yannis Morel ,  Carine Paturel ,  Ivan Perrot

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/68 ,  C07K14/705 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.